Skip to main content
Figure 5 | Molecular Pain

Figure 5

From: Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKCϵ pathway in dorsal root ganglion neurons

Figure 5

PKC, particularly PKCε, but not PKA or Rho, involves in LPA-induced potentiation of TRPV1 currents. Both LPA1 antagonist VPC32183 (1 μM, n = 15, p > 0.05) and PKC inhibitor BIM (1 μM, n = 13, p > 0.05) inhibit potentiation of TRPV1 currents induced by LPA in all of the neurons recorded (A and B). C: After PKA inhibitor H89 (1 μM) was delivered, no effect on LPA-induced potentiation of TRPV1 currents (n = 8, p < 0.001) was observed. D: LPA could still enhance TRPV1 currents in 14 out of 23 neurons tested (p < 0.001) after intracellular delivery of Rho inhibitor BoTXC3 (5 pg/μl). E: Intracellular delivery of PKCε inhibitor εV1-2 (200 μM) completely blocked LPA-induced potentiation of TRPV1 currents (n = 15, p > 0.05). F: Histogram showing summary.

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us